Speciality hub

Haematology

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Haematology.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Haematology is the branch of medicine that deals with disorders or abnormalities in the blood and connected areas such as blood cells, haemoglobin and blood vessels. Haematology also covers bone marrow and spleen, which are the blood producing organs.

Haematology focuses on the study, diagnosis, treatment, and prevention of diseases including coagulation and haemorrhagic disorders such as fibrinogen deficiency, haematological and bone marrow cancers such as leukaemia and lymphoma, and anaemia.

Diseases in this section

Coagulation and Haemorrhagic Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Haematological and Bone Marrow Cancers

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

Learning Zone Homepage

Fibrinogen Deficiency in Bleeding Learning Zone

Fibrinogen is an essential coagulation factor in the blood clotting cascade. The importance for fibrinogen in normal haemostasis is highlighted in patients of inherited fibrinogen deficiencies who display coagulopathies such as excessive bleeding and thrombolytic events.

Learning Zone Homepage

Oral Anticoagulation Reversal Learning Zone

This educational resource is designed to help healthcare professionals diagnose, manage and treat bleeding in patients taking anticoagulants.

Related news and insights

Drug news

AEGIS-H2H study reanalysis shows that Feraccru/Accrufer is a credible alternative to IV therapy for iron deficiency anaemia. -Shield Therapeutics.

Shield Therapeutics plc with its lead product Feraccru/Accrufer (ferric maltol), provides the headline results from the reanalysis of the AEGIS-H2H study .

3 mins

News

Approval of vadadustat as Vafseo in Japan for the treatment of anemia due to chronic kidney disease.- Mitsubishi Tanabe + Akebia

Akebia Therapeutics, Inc.announced the first regulatory approval of vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD).

1 min

News

Idelvion becomes first and only Factor IX therapy with 21-day prophylactic dosing for treating haemophilia B. CSL Behring.

CSL Behring announced that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for Idelvion [albutrepenonacog alfa, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP], CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating haemophilia B.

1 min

See all news

Related drugs

Sytron

Pregaday 322mg / 0.35mg film-coated Tablets

Menstralite 500 mg Tablets

Menadiol Diphosphate 10mg Tablets

Ferrous Sulfate Tablets BP 200mg

Ferrous Sulfate Tablets 200mg

Ferrous Gluconate 300mg Tablets

Ferrous Fumarate 322mg Tablets

Ferrous fumarate 210mg Tablets

Ferrous fumarate 140mg/5ml Syrup

Ferriprox 500 mg & 1000 mg film-coated tablets

Related Guidelines

Guideline

End of life care for infants, children and young people with life-limiting conditions: planning and management

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...

1 mins

Guideline

Management of anaemia and iron deficiency in patients with cancer: ESMO Guidelines

Anaemia and iron deficiency are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents.

1 min

Guideline

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...

1 min

See all guidelines

Your peers are looking at...

Drug news

FDA accepts BLA from Eisai and Biogen for aducanumab, a proposed treatment for Alzheimer’s disease.

1 mins

Drug news

FDA approves supplemental indication of Spravato for major depressive disorder with acute suicidal ideation or behavior. Johnson & Johnson

1 mins

Drug news

FDA approves Olinvyk for management of acute pain.- Trevena

1 mins

Drug news

Phase III CheckMate -743 trial of Opdivo + Yervoy shows efficacy in malignant pleural mesothelioma.- BMS

1 mins

Drug news

Phase III ORIENT-11 trial of Tyvyt plus Alimta shows efficacy in NSCLC.- Innovent Biologics + Eli Lilly

1 mins

Drug news

FDA approves Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. Genentech/Roche

1 mins

Drug news

Pacira announces publication of Phase IV study of Exparel in cesarean section procedures in Anesthesia & Analgesia.

3 mins

Drug news

Cimzia is the first and only biologic approved in Europe with the option for a reduced maintenance dose for patients across the full axial spondyloarthritis spectrum- UCB.

1 mins

Drug news

FDA approves SOMATOM On.site, a mobile head computed tomography (CT) scanner from Siemens Healthineers.

1 mins

Drug news

Genentech/Roche provides update on phase III study Of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer.

1 mins

Related Journals

Journal

Genomic aberrations and survival in chronic lymphocytic leukemia.

1 mins

Journal

Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia.

1 mins

Journal

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

1 mins

Journal

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

1 mins

Journal

Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome

1 mins

$Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.$

Journal

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

1 mins

Journal

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.

1 mins

Journal

Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.

1 mins

Journal

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.

1 mins

Journal

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.

1 mins

Related Events

Conference

9th Translational Research Conference: Myeloproliferative Neoplasms

International Conference

6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment

Scientific Workshop

The Haematological Tumour Microenvironment and its Therapeutic Targeting 2021

Related Clinical Trials

Clinical trial

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

3 mins

$Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia$

Clinical trial

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

3 mins

$A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgki$

Clinical trial

A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgki

3 mins

Clinical trial

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

3 mins

Clinical trial

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

3 mins

Clinical trial

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

3 mins

$Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)$

Clinical trial

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

2 mins

Clinical trial

Study of bb2121 in Multiple Myeloma

3 mins

Clinical trial

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

4 mins

Clinical trial

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

3 mins